The proliferation of observational literature on the topic of high-flow nasal cannula (HFNC) as a therapy for acute viral bronchiolitis is nothing short of remarkable. A brief PubMed search reveals a ratio of observational studies to randomized trials of at least 10 to 1 in the past 3 years alone. This proliferation suggests that, right or wrong, we have embraced the widespread use of HFNC clinically. This ratio also hints at a bigger problem, which is that we have moved on to answering somewhat peripheral questions about the therapy prior to answering the most important questions about clinical utility.

中文翻译：

---

小儿毛细支气管炎患者的高流量鼻导管治疗：是时候把马放回谷仓了。

关于高流量鼻导管 (HFNC) 作为急性病毒性细支气管炎的治疗方法的观察性文献的激增令人瞩目。一个简短的 PubMed 搜索显示，仅在过去 3 年中，观察性研究与随机试验的比率至少为 10 比 1。这种扩散表明，无论对错，我们已经接受了 HFNC 在临床上的广泛使用。这个比率还暗示了一个更大的问题，即在回答有关临床效用的最重要问题之前，我们已经开始回答有关治疗的一些外围问题。